Trial · NCT00834106
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (Test of Hypothesis) | qHPV | 0.3 | Cases per 100 person-years of follow-up | ||
Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (Test of Hypothesis) | Placebo | 1.2 | Cases per 100 person-years of follow-up | ||
Base Study: Combined Incidence of 6-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Years Old Participants (Test of Hypothesis) | qHPV | 0.2 | Cases per 100 person-years of follow-up | ||
Base Study: Combined Incidence of 6-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Years Old Participants (Test of Hypothesis) | Placebo | 1.2 | Cases per 100 person-years of follow-up | ||
| Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis) | qHPV | 0.0 | Cases per 100 person-years of follow-up | ||
| Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis) | Placebo | 0.1 | Cases per 100 person-years of follow-up | ||
| Base Study: Percentage of Participants With One or More Solicited Injection-site Adverse Events | qHPV | 37.6 | Percentage of participants | ||
| Base Study: Percentage of Participants With One or More Solicited Injection-site Adverse Events | Placebo | 27.8 | Percentage of participants | ||
| Base Study: Percentage of Participants With One or More Systemic Adverse Events | qHPV | 50.4 | Percentage of participants | ||
| Base Study: Percentage of Participants With One or More Systemic Adverse Events | Placebo | 48.7 | Percentage of participants | ||
| Base Study: Percentage of Participants Discontinued From Study Vaccination Due to an Adverse Event | qHPV | 0.1 | Percentage of participants | ||
| Base Study: Percentage of Participants Discontinued From Study Vaccination Due to an Adverse Event | Placebo | 0.2 | Percentage of participants | ||
| Entire Study: Percentage of Participants With One or More Vaccine-related Serious Adverse Events | qHPV | 0.0 | Percentage of participants | ||
| Entire Study: Percentage of Participants With One or More Vaccine-related Serious Adverse Events | Placebo | 0.1 | Percentage of participants | ||
| Entire Study: Percentage of Participants Who Died | qHPV | 0.1 | Percentage of participants | ||
| Entire Study: Percentage of Participants Who Died | Placebo | 0.0 | Percentage of participants | ||
Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (End of Study Update) | qHPV | 0.1 | Cases per 100 person-years of follow-up | ||
Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (End of Study Update) | Placebo | 0.7 | Cases per 100 person-years of follow-up | ||
Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Year Old Participants (End of Study Update) | qHPV | 0.0 | Cases per 100 person-years of follow-up | ||
Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Year Old Participants (End of Study Update) | Placebo | 0.6 | Cases per 100 person-years of follow-up |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00834106/results